Blockchain Registration Transaction Record

Soligenix Secures $7.5M Funding to Advance Rare Disease Treatments

Soligenix closes $7.5M public offering to fund rare disease treatments including HyBryte for CTCL and vaccine candidates. Funding extends cash runway through 2026 for clinical development.

This financing directly impacts patients suffering from rare diseases with limited treatment options, particularly those with cutaneous T-cell lymphoma who may benefit from HyBryte's novel photodynamic therapy approach. The extended cash runway through 2026 ensures continued development of multiple therapeutic candidates across oncology, inflammatory diseases, and public health threats. For the broader healthcare landscape, Soligenix's progress represents potential breakthroughs in treating conditions that have historically received limited research attention. The company's vaccine development programs, supported by government agencies, also contribute to pandemic preparedness and biodefense capabilities, making this news relevant to both medical professionals and public health stakeholders.